



ENTER TO LEARN.... EXIT TO SERVE...

Prime College of Pharmacy

Approved by PCI New Delhi & Govt. of Kerala, Affiliated to Kerala University of Health Sciences



INNOVATION AND
ENTREPRENEURSHIP
DEVELOPMENT CENTRE



ACCREDITED WITH "A" GRADE
NAAC
NATIONAL ASSESSMENT AND
ACCREDITATION COUNCIL



ISO
9001:2015



INSTITUTION'S
INNOVATION
COUNCIL
(Ministry of HRD Initiative)

INTRUIZION

THE INSIGHT

Prime Pharma Newsletter Dec 2024

EDITORIAL BOARD

Prof. Dr. N. L. Gowrishankar
Principal, Chief Editor

Mr. Shyam S Kumar,
Assoc. Prof., Co-Editor

MEMBERS – STAFF COMMITTEE

• Prof. Dr. Sumathy. A, Vice Principal, • Mrs. Sruthi. T. P, Asst. Prof. • Dr. T. Sengottuvel, Prof.
• Mrs. Sruthi. T. P, Assoc. Prof • Mrs. Aiswarya. A. T, Assoc. Prof

MEMBERS – STUDENT COMMITTEE

Ms. Naeema C M
VIII Sem B. Pharm

Mr. Mohammed Rafan
VIII Sem B. Pharm



INNOVATION AND
ENTREPRENEURSHIP
DEVELOPMENT CENTRE



ACCREDITED WITH "A" GRADE
NAAC
NATIONAL ASSESSMENT AND
ACCREDITATION COUNCIL



ISO
9001:2015



INSTITUTION'S
INNOVATION
COUNCIL
(Ministry of HRD Initiative)

ORAL ESTROGEN RECEPTOR PROTAC VEPDEGESTRANT (ARV-471) IS HIGHLY EFFICACIOUS IN PRECLINICAL ER+ BREAST CANCER MODELS

PROteolysis-TARgeting Chimera (PROTAC) are induces target protein degradation by the ubiquitin-proteasome system which can potentially treat cancer. Estrogen receptor alpha signaling is a known driver of ER-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become a central strategy in the treatment of ER+ advanced breast cancer. However, suboptimal ER inhibition and resistance resulting from the ESR1 mutation dictates that new therapies are needed. A medicinal chemistry campaign identified vepdegestrant (ARV-471), a selective, orally bioavailable, and potent small molecule PROTAC degrader of ER. Biochemical and intracellular target engagement assays are used to demonstrate the mechanism of action of vepdegestrant, and ESR1 wild-type (WT) and mutant ER+ preclinical breast cancer models to demonstrate ER degradation-mediated tumor growth inhibition (TGI). Vepdegestrant induced ≥90% degradation of wild-type and mutant ER, inhibited ER-dependent breast cancer cell line proliferation in vitro, and achieved substantial TGI (87%-123%) in MCF7 orthotopic xenograft models, better than those of the ET agent fulvestrant (31%-80% TGI). In the hormone independent (HI) mutant ER Y537S patient-derived xenograft (PDX) breast cancer model ST941/HI, vepdegestrant achieved tumor regression and was similarly efficacious in the ST941/HI/ PBR palbociclib-resistant model (102% TGI).



Mrs. Nazrin Fathima. A,
Assistant Professor
Dept. of Pharmaceutical Chemistry

FSSAI CLASSIFIES PACKAGED DRINKING WATER AS ‘HIGH- RISK FOOD CATEGORY’

Packaged drinking water is often considered to be the safest option to beat the thirst in case of unavailability of safe drinking water. But the FSSAI has recently issued an order by the food safety regulator, “Packaged Drinking water and Mineral water” (for which BIS certification was mandatory prior to the First Amendment regulations, 2024, dated October 17, 2024) will now fall under the “High- Risk Food Categories”. This decision follows the removal of mandatory Bureau of India Standards (BIS) certification for certain products, aiming to enhance safety measures and compliance within the industry. In its order, the regulator noted that it has made amendments in its Risk-Based Inspection Policy to include the packaged drinking water and mineral water categories. With this, manufacturers of packaged drinking water and mineral water will undergo risk-based inspection once every year. They will also undergo inspection before the grant of a license or registration.



Ms. Divya k C
Assistant Professor
Dept. of Pharmaceutical Analysis

NATIONAL PHARMACY WEEK CELEBRATIONS 2024

The theme of the year “Think Health, Think Pharmacy” enhance the image of Pharmacists as medication experts and integral parts of the health care team who play an important role in improving people's health through their multiple services. The NSS Unit , IQAC and Dept. of Pharmacy Practice has conducted an Antimicrobial Resistance Awareness Programme in association with District Hospital, Palakkad on 21.11.2024. On behalf of 63rd National Pharmacy Week, Prime College of Pharmacy in association with Indian Pharmacy Graduates’ Association (IPGA, Kerala State Branch) organized a Pharma Rally on 26-11-2024, Tuesday.The well-organized Pharma rally, held from Chittur Anikode Junction to Mini Civil Station was officially inaugurated by Vice Principal Dr. A. Sumathy. Dr.T.Sengottuvel, HOD, Pharmacology, flagged off the rally. In collaboration with Kanjiramkunnam Anganawadi has conducted an Community awareness Programme on 27.11.2024, at Anganwadi and nearby places. Our students provided home based counseling regarding safe and effective use of medicines. We conducted an e-poster competition on the same day. Students from all the batches had given their presentations on different topics from different departments. 28.11.2024, Thursday was the final day of NPW celebrations. Conducted competitions like Quiz, Mime & Tableau and the students from all batches participated wholeheartedly in all the events. The programme wound up with distributing the prizes for the winners of the competitions.



WORLD DIABETES DAY 2024

As part of World Diabetes Day, the Department of Pharmacy Practice, NSS unit & Six Semester B.Pharm Students has conducted the World Diabetes day awareness program on Nov. 18, 2024 at Elappully Taluk Hospital. This year’s theme, “Breaking Barriers, Bridging Gaps,” underpins our commitment to reducing the risk of diabetes, and ensuring that all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care. On behalf of this day, our students distributed pamphlets to educate people about the importance of preventing the disease. They actively took part in the campaign, stressing the significance of effective Diabetes Management and how to improve patients quality of life. Dr. Anoop, Medical Superintendent, Elappully, extended his sincere efforts to make this camp a great success.



BREAST CANCER AWARENESS MONTH 2024

On behalf of this day, Second year Pharm D students of Prime College of Pharmacy ,in association with IQAC and NSS (Unit no. NSS/SFU/PKD/KUHS/1) conducted an awareness program at Government Taluk Hospital, Chittur on 29-10-2024.They circulated the patient information leaflets, focusing the importance of the day, Students counselled them about risk factors, early diagnosis & the prevention of Breast cancer. They were successful in educating and raising awareness about Breast cancer, its risks, symptoms ,and importance of early detection among the public.



DNA EDITING ACHIEVED FOR THE FIRST TIME IN HISTORY:
THE RESULT WAS CONSIDERED TO BE IMPOSSIBLE

This whole concept in genomic science has opened up a whole new revolutionary way of dealing with such critical health issues. There is a possibility that illnesses That were once incurable have a chance to be curable. MedlinePlus provides a definition and states that a collection of tools known as genome editing, or gene editing, allows researchers to alter an organism’s DNA. These technologies enable the addition, deletion, or modification of genetic material at specific genomic regions. A person’s DNA can be altered through gene editing to fix mistakes that lead to illnesses. CRISPR-Cas9, short for CRISPR-associated protein 9 and clustered regularly interspaced short palindromic repeats, is a well-known example as one of the approaches used and developed by scientists to edit DNA. The scientific community is very excited about the CRISPR-Cas9 system since it is more accurate, efficient, quicker, and less expensive than existing genome editing techniques. Using molecular tools, scientists can find the DNA that needs accurate cutting in order to perform the transformation. When these processes are complete, the human body’s natural DNA strand is repaired, consequently, the genetic code is altered. This immune defence mechanism has been modified by researchers to modify DNA. Similar to the RNA segments bacteria generate from the CRISPR array, they produce a tiny bit of RNA with a brief “guide” sequence that binds (attaches) to a particular target region in a cell’s DNA. By correcting the gene at a molecular level, patients can live a life of freedom where they do not have to worry about their health issues, especially chronic diseases.



Mrs. Megha P M
Assistant Professor
Dept. of Pharmaceutics

NETWORK PHARMACOLOGY

A new discipline called network pharmacology (NP) has emerged which attempts to understand drug actions and interactions with multiple targets. It uses computational power to systematically catalogue the molecular interactions of a drug molecule in a living cell. NP appeared as an important tool in understanding the underlying complex relationships between botanical formula and the whole body. It also attempts to discover new drug leads and targets and to repurpose existing drug molecules for different therapeutic conditions by allowing an unbiased investigation of potential target spaces. However, these efforts require some guidance for selecting the right type of targets and new scaffolds of drug molecules. Traditional knowledge can play a vital role in this process of formulation discovery and repurposing existing drugs. By combining advances in systems biology and NP, it might be possible to rationally design the next generation of promiscuous drugs.



Mrs. Akhila A
Assistant Professor
Dept. of Pharmaceutical Chemistry

CO-FORMULATION OF SEMAGLUTIDE AND CAGRILINTIDE SHOWS PROMISE AGAINST DIABETES AND OBESITY

The modern era has seen an alarming rise in the prevalence of obesity and type 2 diabetes. Lifestyle interventions such as diet and exercise remain cornerstones of treatment, pharmaceutical advancements are providing promising new options for individuals struggling with these chronic conditions. One such advancement is a co-formulation of semaglutide and cagrilinitide (CagriSema, Novo Nordisk) a novel drug combination currently in phase 3 clinical trials designed to address both weight loss and glycemic control in a way that is highly effective and manageable for patients. Cagrilintide is a long-acting amylin analog, whereas semaglutide is a well-known glucagon-like peptide-1 (GLP-1) receptor agonist. Both of these drugs act on different hormonal pathways to achieve significant effects on weight loss and blood glucose control. Together, they form a potent combination that may offer enhanced benefits over existing therapies. Amylin is a hormone co-secreted with insulin by the pancreas in response to food intake. It works by slowing gastric emptying, reducing food intake, and modulating postprandial glucose spikes. Cagrilintide, a synthetic analog of amylin, has been developed to produce these same effects while being more stable and long acting than the native hormone. Meanwhile, GLP-1 (glucagon-like peptide-1) receptor agonists like semaglutide have been established as effective treatments for type 2 diabetes and, more recently, for obesity.



Ms. Niranjana C M
Assistant Professor
Department of Pharmaceutical Analysis

NEW ASTHMA GUIDELINE

New guidelines published today (November 27) advise prescribing only combination treatments for people with newly diagnosed asthma.

- For the first time, the BTS, NICE & SIGN have jointly produced new UK-wide guidance for diagnosing and managing chronic asthma in adults, young people and children.
- Healthcare practitioners should offer a low-dose combination of inhaled corticosteroids & formoterol
- Short-acting beta-2 agonists are no longer recommended without inhaled corticosteroids using FeNO breath tests and measuring eosinophil levels
- The independent guideline committee considered evidence which showed using combined ICS and formoterol inhalers led to people suffering fewer severe asthma attacks.
- The asthma pathway includes existing BTS/SIGN guidance on management of acute asthma, non-pharmacological management and occupational asthma.



Mrs. Sangeetha R
Assistant Professor
Department of Pharmaceutics

GRADUEREN 2024 – THE GRADUATION CEREMONY

Prime College of Pharmacy successfully organized the graduation ceremony, GRADUEREN 2024 for the 2019 B Pharmacy batch on 12-11-2024. Dr. Rajasree. R.S, Dean of Pharmaceutical Sciences at KUHS graced the event as the Chief guest. The auspicious ceremony commenced with the grand entry of academic procession. Prof. Dr.C.I Sajeeth, Executive Trustee, delivered the Presidential address. The grand ceremony was inaugurated by Prof. Dr. Rajasree. R.S, Dean of Pharmaceutical Sciences, KUHS. The Key note address was delivered by the Secretary, Mr.B.Rahim, which was followed by the declaration of graduation ceremony by the Chief guest. The enlightening part of the session was the distribution of academic excellence awards to the rank holders. Mrs.Fitha.T.V of 2020 M Pharm Pharmaceuticals batch was awarded with gold medal, certificate and memento for securing third rank from Kerala University of Health Sciences by the Chief guest Dr. Rajasree R. S. The Chairman, Dr.P.A. Mohammed Ashraf distributed the Gold medal, Memento and certificate to the topper of 2019 B Pharmacy batch, Ms.Swathi Sivan. Mr.B.Rahim, Secretary, awarded Cash prize, Memento and certificate to Ms.Shabana Rinsi M K, for securing the second position. Prof.Dr. C.I Sajeeth, Executive Trustee awarded Cash prize, Memento and certificate to Ms.Devichandana.V.S for her third position. It was followed by the Conferral of degree by the honourable Chief guest. She awarded the graduands with the certificates.



ANTI- DRUG CAMPAIGN 2024

We organized an awareness programme as a part of Anti- drug campaign in association with Vimukthi Mission and Kerala Excise Department on 01/11/2024. Dr. N.L.Mr.M. Rakesh, Deputy Excise Commissioner, Palakkad, delivered the inaugural address. He distributed the first prize of Rs. 18,000 for the State wide short film competition organized by Kerala Niyama Sabha Secretariat in association with Kerala Legislative Assembly Media and Parliamentary Study Centre to promote awareness against Drug Abuse. All the participants of the prize winning short Film titled “ZARAR” were congratulated for their dedication and hard work to make it a success. The core of the event was the talk by Mr. M. N. Suresh Babu, Assistant Excise Inspector, Palakkad on “Awareness on Drug Use Among Students”.



SWACHHATA HI SEWA CAMPAIGN

On the occasion of the third anniversary of the Swachh Bharat Mission and Gandhi Jayanti, the Hon'ble Prime Minister initiated the Swachhata Hi Sewa campaign, "Cleanliness is Service," from 17th September 2024 to 2nd October 2024 in association with this NSS unit organized a cleaning campaign on 3/10/2024. The cleaning campaign was inaugurated by Mrs. Jyothi A, NSS program officer and a session about the importance of campaign was given by the Mrs. Sruthi T P, Associate Professor, Department of Pharmaceutics. She explained about the importance of cleanliness and sanitation, how to maintain personal and community hygiene. The NSS volunteers of Fourth Semester effectively participated in the cleaning campaign conducted in and around the college campus. The students collected the wastes and separated into the biodegradable and recyclable wastes. They took the pledge to maintain the campus as well as the outside campus neat and cleanliness.



INSITRO.... BETTER DRUGS THROUGH AI?

Insitro is a biotechnology company at the forefront of integrating machine learning (ML) and data-driven approaches into drug discovery and development. Insitro is part of a growing field of AI companies promising to accelerate drug discovery by using machine learning to analyze huge datasets of chemical and biological markers. The company has signed deals with drug makers like Eli Lilly & Bristol Myers Squibb to help develop medicines for metabolic diseases, neurological conditions and degenerative disorders. By combining advanced biology, scalable data generation, & state-of-the-art ML, Insitro's approach to drug discovery not only accelerates the identification of effective therapies but also increases the likelihood of success in the clinic. This strategy aims to reduce costs, shorten development timelines, and improve patient outcomes. In drug discovery, Insitro uses advanced Machine learning models to analyze large datasets, including genomic, proteomic, and cellular data, to uncover novel therapeutic targets and predict drug responses. It focuses on generating high-quality biological data, such as from human induced pluripotent stem cells (hiPSCs), which are systematically studied to create predictive in vitro models of disease. But the pharmaceutical industry is still waiting to see whether AI can tackle its biggest challenge: finding faster, cheaper ways to develop new drugs.



Mrs. Pradeepa. P
Associate Professor
Dept. of Pharmacology

NALTREXONE BLOCKS ALCOHOL-INDUCED EFFECTS ON KAPPA-OPIOID RECEPTORS IN THE PLASMA MEMBRANE

Naltrexone (NTX), a homolog of the opiate antidote naloxone, is an orally active long-acting general opioid receptor antagonist used in the treatment of opiate dependence. NTX is also found to relieve craving for alcohol and is one of few FDA-approved medications for treatment of alcohol use disorder (AUD). While it was early on established that NTX acts by blocking the binding of endogenous opioid peptide ligands released by alcohol, suggesting that NTX may have additional modes of action. Mu- and kappa-opioid receptors are structurally related G-protein-coupled receptors, often mediating opposite responses, with MOP typically promoting euphoria and reward, while KOP is associated with dysphoria and aversive states. While the actions of NTX on MOP are extensively characterized, the interactions with KOP are not. Here, we used sensitive fluorescence-based methods with single molecule sensitivity to study in live cells the influence of alcohol (ethanol, EtOH) on KOP and the interaction between KOP and NTX. Alcohol, at relevant concentrations (10–40 mM), alters KOP interactions with the lipid environment in the plasma membrane. The counteracting effects of NTX are exerted by both its canonical action on KOP and its hitherto unrevealed effects on the lateral dynamics and organization of lipids in the plasma membrane.



Dr. Sabitha. T. B
Associate Professor
Dept. of Pharmacology

NOVEL THIENOPYRIMIDINE-HYDRAZINYL COMPOUNDS INDUCE DRP1-MEDIATED NON-APOPTOTIC CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER CELLS

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal receptors. This lack of receptors renders TNBC unsuitable for targeted-based treatment, making it the most fatal and aggressive subtype of breast cancer. TNBC has a greater relapse rate, worse prognosis, and increased metastasis rate compared to non-TNBC because of its tendency to resist apoptosis, a programmed cell death triggered by most chemotherapeutic drugs, producing anticancer efficacy. Apoptosis induction with taxanes or anthracyclines is the primary therapy for TNBC. Cancer cells can develop resistance to anticancer drugs, causing them to recur and metastasize. Therefore, non-apoptotic cell death inducers could be a potential treatment to circumvent apoptotic drug resistance. In this study, we discovered two novel compounds, TPH104c and TPH104m, which induced non-apoptotic cell death in TNBC cells. These lead compounds were 15- to 30-fold more selective in TNBC cell lines and significantly decreased the proliferation of TNBC cells compared to that of normal mammary epithelial cell lines. TPH104c and TPH104m induced a unique type of non-apoptotic cell death, characterized by the absence of cellular shrinkage and the absence of nuclear fragmentation and apoptotic blebs. Although TPH104c and TPH104m induced the loss of the mitochondrial membrane potential, TPH104c- and TPH104m-induced cell death did not increase the levels of cytochrome c & intracellular reactive oxygen species



Mrs. Shamna. Z
Assistant Professor,
Dept. of Pharmaceutical Chemistry

IN SILICO FORMULATION OPTIMIZATION & PARTICLE ENGINEERING OF PHARMACEUTICAL PRODUCTS USING A GENERATIVE AI STRUCTURE SYNTHESIS METHOD

Generative AI method that creates digital versions of drug products from images of exemplar products. This approach employs an image generator guided by critical quality attributes, such as particle size and drug loading, to create realistic digital product variations that can be analyzed and optimized digitally. This method was validated through two case studies: one for the determination of the amount of material that will create a percolating network in an oral tablet product and another for the optimization of drug distribution in a long-acting HIV inhibitor implant. The results demonstrate that the generative AI method accurately predicts a percolation threshold of 4.2% weight of microcrystalline cellulose and generates implant formulations with controlled drug loading and particle size distributions. Comparisons with real samples reveal that the synthesized structures exhibit comparable particle size distributions and transport properties in release media.



Mr. Shebin A
Assistant Professor
Dept. of Pharmaceutics

WORLD HEART DAY 2024

On behalf of this day, Sixth Semester B Pharmacy students of Prime College of Pharmacy in association with IQAC and NSS and Pharmacy Practice Department conducted an awareness programme at Family Health Centre Pudukkottai, Palakkad on 28-09-2024, Saturday. In an effort to lower the risk of Heart problems, our students distributed pamphlets to the public, educating them on the risk factors and benefits of leading a healthy lifestyle. The program was started with a Welcome speech by Junior Health Inspector, Mrs. Priya. A session about prevention of Cardiovascular diseases was given by Prof. Dr. P Sivakumar, Professor and HOD, Department of Pharmacy Practice and Dr. Aparna S S, Assistant Professor, Department of Pharmacy Practice of Prime College of Pharmacy.



FIELD VISIT TO M/S LABINDUSS LTD 2024

Prime College of Pharmacy successfully organized a field visit dated on 27/09/2024 for first year D. Pharmacy Students (2023 batch) with Placement in-charge Mr. A. Mohamed Harish, and staff coordinator Mrs. Aysumma C.U to the Labinduss Ltd, Pharmaceutical Company, Kanjikode, Palakkad. Mr. Sanjay, Production Manager, Labinduss Ltd, explained the students about the various liquid, oral and external preparations. The purpose of this field visit was to gain insight into the company's operations, quality control measures and product development processes. It was very useful for the



WORLD PHARMACIST DAY

World Pharmacists’ day is celebrated globally on 25th September every year. This day is celebrated to advocate and appreciate the role of Pharmacist in improving health conditions around the world. Pharmacists are integral to our health-care systems, often being the first point of contact for health advice and primary health care, as well as addressing the health needs of our populations in many varied ways. The theme of this year is “Pharmacists: Meeting global health needs” according to the International Pharmaceutical Federation (FIP).On behalf of this day, Prime College of Pharmacy in association with IQAC, celebrated World Pharmacist Day with the wholehearted involvement of students, staffs and management on 25/09/2024 at College auditorium. The programe started with the welcome address by Vice Principal , Dr.A.Sumathy followed by inaugural address by the Principal, Dr. N. L. Gowrishankar. The students of different batches presented a session on the various facets of Pharmacy profession along with the responsibilities and challenges of this profession. Dr. K Selvaraju, Head of the Department, Department of Pharmaceutics conducted Pharma Quiz 2024 for the B. Pharmacy and D Pharmacy students. Students showed great enthusiasm to be a part of the event and more than 150 students actively involved in the session. The prize distribution to the winners was awarded by Principal, Dr. N. L. Gowrishankar.



WORLD PATIENT SAFETY DAY

World Patient Safety day 2024 focuses on “Improving Diagnosis For Patient Safety” with the slogan “ GET IT RIGHT, MAKE IT SAFE” . This year’s theme highlights the critical importance of accurate and timely diagnosis in ensuring patient safety and improving health outcomes. We conducted an awareness programme on 26.09.24,. Dr. Varsha V K, Asst. Prof., Dept. of Pharmacy Practice presented a seminar on “Improving Diagnosis For Patient Safety” for the VI Semester B Pharmacy Students at Seminar hall. In her talk, she explained about the methods of generating accurate medical history taking through physical examination.



TRENDS IN TREATING UNRESECTABLE OR METASTATIC HER2-POSITIVE (IHC 3+) BILIARY TRACT CANCER

There is a new drug approved by the US FDA on November 20, 2024, ZIIHERA,a game-changing medication in the treatment of unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. A summary of the newer drug is given below for the interest of readers to get more insight into the drug.

Mechanism of action

Zanidatamab-hrii is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2.Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptoron the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC),antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis(ADCP).

Indications and usage

ZIIHERA is indicated for the treatment of adults with previously treated, unresectable or metastaticH-ER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.This indication is approved under accelerated approval based on the overall response rate and durationofresponse.

Dosage & Administration

Recommended Dosage

The recommended dosage of ZIIHERA is 20 mg/kg, administered as an intravenous infusion once every 2 weeks until disease progression or unacceptable toxicity. Premedicate all patients 30 to 60 min prior to each dose of ZIIHERA to reduce the risk ofinfusion-relatedreactions.

Dosage Modifications for Adverse Reactions

The recommended dosage reduction of ZIIHERA for adverse reactions is 15 mg/kg. Permanently discontinue ZIIHERAv in patients who cannot tolerate 15mg/kg. Warnings and Precautions should be noted when Administering acetaminophen, an antihistamine (such as diphenhydramine), and a corticosteroid (such as hydrocortisone).

Administration

AdministerZIIHERAasanintravenousinfusionwitha0.2or0.22micronfilter.

Donotadminister asan intravenous pushor bolus.

Donotco-administerZIIHERAandotherintravenousdrugsthroughthesameintravenousline.

Recommended ZIIHERA Infusion Durations

Dose Infusion Duration

FirstandSecond 120-150minutes

ThirddandFourth 90minutes,ifpreviousinfusions werewell-tolerated

Subsequent 60minutes,ifpreviousinfusions werewell-tolerated



Dr. A. Sumathy
Professor
Dept. of Pharmaceutical Chemistry

KNOW ABOUT LIPOPROTEIN (A) BLOOD TEST

What is a Lipoprotein (a) Blood Test?

A lipoprotein (a) test measures the level of lipoprotein (a) in your blood. A high level of lipoprotein (a) may mean you have a high risk for heart disease and stroke. Lipoproteins are particles made of protein and fats (lipids). They carry cholesterol through your bloodstream to your cells. The two main groups of lipoproteins are called HDL (high-density lipoprotein) or "good" cholesterol and LDL (low-density lipoprotein) or "bad" cholesterol. Lipoprotein (a) is a type of LDL. These lipoproteins carry cholesterol to the cells in your arteries. If you have high levels of LDL particles, cholesterol can build up in your arteries and form blockages called plaques. This condition is known as atherosclerosis or "hardening of the arteries." It can lead many serious medical conditions including:

- Coronary artery disease
- Heart attack
- Stroke
- Peripheral arterial disease, blocked arteries in your legs or arms
- Other blood vessel diseases

Lipoprotein (a) particles are stickier than other types of LDL particles, so they may be more likely to cause blockages and blood clots in your arteries. As a result, high levels of lipoprotein (a) may mean you have a very high risk for heart disease, stroke, and other serious conditions related to blockages and blood clots in your arteries. A lipoprotein (a) blood test can give you a more accurate understanding of your risk than a routine cholesterol test that only measures your total LDL cholesterol level. That's because a routine cholesterol test may show that your LDL cholesterol level is "healthy," but if a large percentage of your LDL cholesterol is carried by lipoprotein (a) particles, your risk for heart disease and stroke could still be high.

What is it used for?

A lipoprotein (a) test is used to get a better understanding of your risk for heart disease, stroke, and other blood vessel diseases. But it is not a routine screening test. Researchers are still studying how lipoprotein (a) levels affect health and when the test should be used.

Why do I need a lipoprotein (a) test?

- A family health history of early heart or blood vessel disease
- High LDL cholesterol, even though you take medicine to lower it
- Heart or blood vessel disease
- Signs of an inherited condition called familial hypercholesterolemia
- Had more than one heart attack or more than one procedure to open up narrow or angioplasty

The test may also be used to help make decisions about the risks and benefits of taking cholesterol medicine to lower your chance of developing heart and blood vessel disease.



Dr. T. Sengottuvel,
Prof & HOD,
Dept. of Pharmacology

NSS DAY CELEBRATION 2024

The Ministry of Youth Affairs & Sports of the Gov. of India oversees the National Service Scheme (NSS), a central sector program. Nationwide, September 24th is recognised as NSS Day each year. Its' primary goal is to close the gap that exists between local communities and educational institutions, with a focus on rural areas. "Not Me But You" is the motto of NSS day. It enables students to participate in a range of community service initiatives run by the Government. It is a unique opportunity to recognise and appreciate the contributions made by each volunteer in promoting the welfare of the community as a whole. Prime College of Pharmacy, in association with IQAC and NSS unit (NSS/SFU/PKD/KUHS/1) organized a program in relation to this day. The program begun with the prayer song followed by the NSS day speech by Aroma Sachin, Fourth Semester B Pharmacy student, Prime College of Pharmacy. She stressed out the importance of the day and motivated the students to increase their participation in community services. The NSS flag was hoisted by Vice Principal, Dr. A. Sumathy. Fathimath Shibla of Fourth Semester B Pharmacy took the pledge, followed by the NSS song and NSS clap.



ONAM CELEBRATION

Onam , the traditional harvest festival of Kerala was celebrated with great enthusiasm and fervor on 13/09/2024 at college auditorium involving students, staffs and management. The event aimed to promote cultural unity and showcase the rich heritage of Kerala. The celebrations started with setting up of an attractive floral decoration (pookalam). The celebration was inaugurated by Principal, Prof. Dr. N. L Gowrishankar. The main attractions of the programme were Pookalam competition and Thiruvathirakali conducted among students. Students participated in the various programs with great enthusiasm and joy. The traditional Onam Sadya was served to the gathering .The onam celebration ends with cul- tural events like musical chair, lemion spoon, sack race etc.at the campus.

